GeNeuro SA Declares Bankruptcy Following Debt Moratorium

GeNeuro SA, a biopharmaceutical firm based in Geneva, has been declared bankrupt. The Geneva Court of First Instance ruled this on January 28, 2026, after not extending the company’s debt moratorium. The moratorium, initially granted on September 26, 2025, was meant to allow GeNeuro SA to explore options like recapitalization and creditor agreements.

Despite the scientific promise of its treatments for neurodegenerative and autoimmune diseases, GeNeuro SA failed to secure a recovery or restructuring plan. Consequently, the court opted not to extend the moratorium period. The bankruptcy judgment will be published in official Geneva and Swiss commerce bulletins.

Creditors will be prioritized over shareholders due to the company's debts, suggesting minimal recovery prospects for the latter. Future updates will be managed by the Geneva Cantonal Bankruptcy Office.